Suvorexant: Difference between revisions

Nav

(View all pending changes)

[checked revision]

[pending revision]

← Older edit Newer edit →

VisualWikitext

@@ Line 1: / Line 1: @@
 {{MedTemplate
-| generic            = Suvorexant
+| brand           = Belsomra
-| brand              = Belsomra
+| classes         = Dual orexin receptor antagonist (DORA), the first approved
-| structure          =
+| mechanism       = Competitive antagonist at OX1R and OX2R. First-in-class DORA. Receptor dissociation slower than lemborexant or daridorexant.
-| classes            = Sedative-Hypnotic
+| uses            = Insomnia (sleep onset and/or maintenance) in adults (FDA-approved August 2014). Also studied for insomnia in mild-moderate Alzheimer disease.
-| mechanism          = Dual orexin receptor antagonist
+| starting_dose   = 10 mg PO 30 min before bedtime (with ≥7 hours of sleep planned)
-| uses               =
+| preparations    = 5 mg, 10 mg, 15 mg, 20 mg tablets
-| starting_dose      =
+| fda_max         = 20 mg/d
-| preparations       =
+| routes          = Oral
-| fda_max           =
+| onset           = ~30 min
-| routes             =
+| duration        = ~7-8 hours
-| onset              =
+| halflife        = ~12 hours
-| duration           =
+| bioavailability = ~82%
-| halflife           =
+| pregnancy       = Limited data; avoid
-| bioavailability    =
+| legal           = Rx, Schedule IV (US)
-| pregnancy          =
+| intro           = '''Suvorexant''' (brand name Belsomra) is the first FDA-approved dual orexin receptor antagonist (DORA), approved August 2014 for insomnia. Suvorexant established the DORA class as a treatment paradigm, reducing arousal via orexin blockade rather than enhancing GABA-mediated inhibition. Subsequent DORAs (lemborexant 2019, daridorexant 2022) have been positioned as iterative improvements with different pharmacokinetics.
-| legal              =
-| intro              =
+Suvorexant has been studied in mild-moderate Alzheimer disease with positive results; trials have suggested potential for reducing sleep-disordered breathing exacerbations and possibly delaying cognitive decline (though the cognitive claim remains controversial).
-| pharmacokinetics   =
+| pharmacodynamics= Competitive antagonist at OX1R (Ki ~0.55 nM) and OX2R (Ki ~0.35 nM). Receptor dissociation slower than lemborexant or daridorexant.
-| pharmacodynamics   =
+| effects         = Next-day somnolence (more common than with daridorexant due to longer half-life), headache, abnormal dreams, dry mouth, fatigue. Sleep paralysis and hallucinations near sleep onset. Complex sleep behaviors class warning.
-| indications        =
+| interactions     = <pharmaInteractions/>
-| dosing             =
-| effects            =
-| interactions       = <pharmaInteractions/>
-| pregnancy_details  =
-| monitoring         =
-| counseling         =
-| anecdotes          =
-| seealso            =
-| references         =
 }}
+[[Category:Anxiolytics & Sedative-Hypnotics]]
+[[Category:Orexin Receptor Antagonists]]
 [[Category:Sedative-Hypnotics]]
+[[Category:Hypnotics]]
+[[Category:Orexin Antagonists]]

MDElliottMD (talk | contribs)